TokenPost·
European Commission Expands Keytruda-Padcev Use for Cisplatin-Eligible MIBC
79.4%
event-free survival
A Phase 3 trial found 24-month event-free survival of 79.4% with the combination, versus 66.2% with gemcitabine-cisplatin.
More news
- TokenPostSky Prime Agent’s Basin Targets Settlement Timing Gap for Tokenized Treasury Bills
- TokenPostGM Plans Hybrids Across Several Segments as Toyota Electrified Sales Rise
- TokenPostNVIDIA Brings Agile Robots Humanoid System Into Isaac Platform
- TokenPostChipotle Reports 2.2% Comparable Sales Growth for Second Quarter
- TokenPostFirst Trust Sets FPEI’s October Distribution at $0.0955 Per Share
- TokenPostSuper Micro Computer Shares Lead S&P 500 With 9.12% Midday Gain